ORKA
Bearish signalScored 2026-10-22 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Oruka Therapeutics, Inc.
- Nom
- Oruka Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $5.3B
- Employés
- 68
- PDG
- Lawrence Otto Klein
- Site web
- http://www.orukatx.com
- Marché
- ACRSALMSANABATTOCNTBDNTH
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 102 452 titres (~9 128 638,42 $ US)
- Insiders
- Klein Lawrence Otto
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,950,846
Avg sell (VWAP, 90d window) $97.10 vs last close $90.33 (-7.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$2,291,535 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Liquid $87,383,968/day · 20d vol
- Last synced
-
2026-10-26 21:10:48
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-20 | Quinlan Paul T | Sell · S | 3,000 | $79.49 | $238,474 | Form 4 |
| 2026-10-15 | Goncalves Joana | Sell · S · 10b5-1 | 200 | $77.71 | $15,542 | Form 4 |
| 2026-10-12 | Agarwal Arjun | Sell · S · 10b5-1 | 200 | $82.83 | $16,567 | Form 4 |
| 2026-10-01 | Klein Lawrence Otto | Sell · S · 10b5-1 | 200 | $84.78 | $16,956 | Form 4 |
| 2026-09-21 | Agarwal Arjun | Sell · S · 10b5-1 | 533 | $95.75 | $51,035 | Form 4 |
| 2026-09-21 | Quinlan Paul T | Sell · S · 10b5-1 | 2,667 | $95.31 | $254,196 | Form 4 |
| 2026-09-15 | Agarwal Arjun | Sell · S · 10b5-1 | 560 | $95.71 | $53,598 | Form 4 |
| 2026-09-15 | Goncalves Joana | Sell · S · 10b5-1 | 947 | $95.71 | $90,637 | Form 4 |
| 2026-09-15 | Klein Lawrence Otto | Sell · S | 2,452 | $95.71 | $234,681 | Form 4 |
| 2026-09-15 | Quinlan Paul T | Sell · S | 1,039 | $95.71 | $99,443 | Form 4 |
| 2026-09-15 | Sandler Laura Lee | Sell · S | 906 | $95.71 | $86,713 | Form 4 |
| 2026-09-11 | Agarwal Arjun | Sell · S · 10b5-1 | 200 | $94.02 | $18,803 | Form 4 |
| 2026-09-01 | Klein Lawrence Otto | Sell · S · 10b5-1 | 4,800 | $92.44 | $443,691 | Form 4 |
| 2026-09-01 | Sandler Laura Lee | Sell · S · 10b5-1 | 4,000 | $92.01 | $368,054 | Form 4 |
| 2026-08-17 | Goncalves Joana | Sell · S · 10b5-1 | 2,480 | $112.56 | $279,154 | Form 4 |
| 2026-08-14 | Quinlan Paul T | Sell · S · 10b5-1 | 3,847 | $111.14 | $427,547 | Form 4 |
| 2026-08-13 | Agarwal Arjun | Sell · S · 10b5-1 | 2,358 | $108.46 | $255,755 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-22 Drivers: fundamentals. Moteurs : fondamentaux.
ORKA is a pre-revenue entity with severe financial distress (liquidity score 25, fundamentals trend 15), zero revenue, and negative operating cash flows, making it structurally fragile.
The first sentence of the analysis written for ORKA on 2026-10-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Bearish signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Unavailable or mixed. Weekly bias is flat
- Financial indicators Supports a bullish reading. Current ratio 22.37 · operating margin 0.0%
Suggested stop 83.80, nearest stored support minus 0.5 ATR(7.2% under the last close). Reward/risk to the next stored resistance is 0.10. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 Oruka Therapeutics (NASDAQ:ORKA) Stock Keeps “Buy” Rating at BTIG Research Oruka Therapeutics (NASDAQ: ORKA - Get Free Report)''s stock had its "buy" rating restated by analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They currently have a $151.00 price target on the stock. BTIG Research''s price objective would indicate a potential upside of 98.59% from the stock''s current price. Several other
- 2026-10-18 Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End Oruka Therapeutics is positioned as a leader in ultra-long-acting injectable treatments for psoriasis, with ORKA-001 showing class-leading efficacy. ORKA-001''s PASI 100 and PASI 90 rates at Week 28 reinforce its durability, while a replicated response in the crossover cohort strengthens confidence in trial results. ORKA''s $1.1B cash balance, exclusive Hypercon technology license, and pipeline breadth provide funding through BLA and strategic flexibility amid rising R&D spend.
- 2026-09-24 ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data Oruka''s ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.
- 2026-09-23 Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy Oruka Therapeutics Inc. (NASDAQ:ORKA) on Wednesday reported positive week 28 outcomes from its Phase 2a clinical trial evaluating ORKA-001 for moderate-to-severe plaque psoriasis.
- 2026-09-23 Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained a favorable safety and tolerability profile through Week 28 52-week EVERLAST-A data for all patients expected in December 2026 16-week EVERLAST-B data expected in 4Q 2026 MENLO PARK, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis.
- 2026-09-09 Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference MENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its attendance at the 2026 Morgan Stanley Global Healthcare Conference, taking place in New York, NY from September 14-16, 2026. About Oruka Therapeutics Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka''s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
- 2026-08-28 ORKA Stock Up More Than 60% in 3 Months: Here''s What You Should Know Oruka''s three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.
- 2026-08-25 BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA BlackRock Inc. purchased a new position in Oruka Therapeutics, Inc. (NASDAQ: ORKA) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,990,181 shares of the company''s stock, valued at approximately $474,916,000. BlackRock Inc. owned about 8.27% of Oruka
- 2026-08-24 Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026.
- 2026-08-11 4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026 PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 22.366 | 28.894 | 59.014 | 37.720 | 15.558 | |
| Quick Ratio | 22.366 | 28.894 | 59.014 | 37.720 | 15.558 | |
| Solvency Ratio | -6.313 | -6.066 | -6.216 | -6.949 | -4.955 | |
| Cash Ratio | 3.053 | 4.721 | 58.761 | 37.496 | 15.254 | |
| Price To Earnings Ratio | -13.121 | -3.886 | -4.595 | -3.439 | -1.547 | |
| Price To Earnings Growth Ratio | 0.244 | -0.314 | 0.099 | 0.068 | -0.016 | |
| Forward Price To Earnings Growth Ratio | 0.244 | -0.314 | 0.099 | 0.068 | -0.016 | |
| Price To Earnings Diluted Ratio | -13.121 | -3.886 | -4.595 | -3.439 | -1.547 | |
| Price To Earnings Diluted Growth Ratio | 0.244 | -0.314 | 0.099 | 0.068 | -0.016 | |
| Price To Book Ratio | 2.930 | 0.852 | 7.944 | 9.834 | 7.028 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -15.637 | -5.610 | 0.000 | -37.550 | -19.076 | |
| Price To Operating Cash Flow Ratio | -15.674 | -5.629 | 0.000 | -37.557 | -19.119 | |
| Debt To Assets Ratio | 0.004 | 0.002 | 0.007 | 0.009 | 0.009 | |
| Debt To Equity Ratio | 0.004 | 0.003 | 0.008 | 0.009 | 0.009 | |
| Debt To Capital Ratio | 0.004 | 0.003 | 0.008 | 0.009 | 0.009 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.035 | 1.036 | 1.023 | 1.034 | 1.076 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -5.738 | -4.434 | 0.000 | -9.640 | -5.364 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.003 | 0.000 | 1.000 | 1.002 | |
| Debt Service Coverage Ratio | -170.194 | -48.917 | -68.789 | -95.262 | -192.310 | |
| Interest Coverage Ratio | 0.000 | -60.029 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -142.504 | -271.535 | 0.000 | -105.942 | -187.620 | |
| Operating Cash Flow Coverage Ratio | -45.657 | -59.749 | 0.000 | -28.491 | -38.845 | |
| Capital Expenditure Coverage Ratio | -422.057 | -306.016 | 0.000 | -5,456.000 | -436.326 | |
| Dividend Paid And Capex Coverage Ratio | -422.057 | -0.178 | 0.000 | -5,456.000 | -436.326 | |
| Dividend Payout Ratio | 0.000 | -3.882 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -12.696 | -3.222 | -49.146 | -37.481 | -15.904 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 22.366 | ▼-6.528 | ▼-10.344 |
| Quick Ratio | 22.366 | ▼-6.528 | ▼-10.344 |
| Solvency Ratio | -6.313 | ▼-0.247 | ▼-0.213 |
| Cash Ratio | 3.053 | ▼-1.668 | ▼-20.804 |
| Price To Earnings Ratio | -13.121 | ▼-9.235 | ▼-7.804 |
| Price To Earnings Growth Ratio | 0.244 | ▲0.558 | ▲0.228 |
| Forward Price To Earnings Growth Ratio | 0.244 | ▲0.558 | ▲0.228 |
| Price To Earnings Diluted Ratio | -13.121 | ▼-9.235 | ▼-7.804 |
| Price To Earnings Diluted Growth Ratio | 0.244 | ▲0.558 | ▲0.228 |
| Price To Book Ratio | 2.930 | ▲2.078 | ▼-2.788 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -15.636 | ▼-10.026 | ▼-0.062 |
| Price To Operating Cash Flow Ratio | -15.674 | ▼-10.045 | ▼-0.078 |
| Debt To Assets Ratio | 0.004 | ▲0.002 | ▼-0.002 |
| Debt To Equity Ratio | 0.004 | ▲0.002 | ▼-0.003 |
| Debt To Capital Ratio | 0.004 | ▲0.002 | ▼-0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.035 | ▼-0.001 | ▼-0.005 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -5.738 | ▼-1.303 | ▼-0.703 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▼-0.001 | ▲0.201 |
| Debt Service Coverage Ratio | -170.194 | ▼-121.277 | ▼-55.099 |
| Interest Coverage Ratio | 0.000 | ▲60.029 | ▲12.006 |
| Short Term Operating Cash Flow Coverage Ratio | -142.504 | ▲129.031 | ▼-0.984 |
| Operating Cash Flow Coverage Ratio | -45.657 | ▲14.092 | ▼-11.109 |
| Capital Expenditure Coverage Ratio | -422.057 | ▼-116.041 | ▲902.022 |
| Dividend Paid And Capex Coverage Ratio | -422.057 | ▼-421.880 | ▲840.855 |
| Dividend Payout Ratio | 0.000 | ▲3.881 | ▲0.776 |
| Enterprise Value Multiple | -12.696 | ▼-9.474 | ▲10.993 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.38B | $325.5M | $294.1M | $409.8M | $358.7M | |
| Enterprise value | $1.34B | $264.9M | $256.9M | $367.8M | $305.8M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -15.16x | -4.58x | 0.00x | -33.70x | -16.30x | |
| EV / Free cash flow | -15.13x | -4.57x | 0.00x | -33.70x | -16.26x | |
| EV / EBITDA | -12.70x | -3.22x | -49.15x | -37.48x | -15.90x | |
| Net debt / EBITDA | 0.43x | 0.74x | 7.11x | 4.29x | 2.75x | |
| Current ratio | 22.37x | 28.89x | 59.01x | 37.72x | 15.56x | |
| Income quality | 0.84x | 0.69x | 0.00x | 1.10x | 0.97x | |
| Graham net-net | $7 | $22 | $3 | $3 | $4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 101.8% | 100.0% | 100.0% | 100.0% | |
| Working capital | $328.5M | $363.8M | $37.0M | $41.6M | $50.9M | |
| Invested capital | $330.6M | $364.9M | $37.2M | $41.9M | $51.4M | |
| Return on assets | -21.6% | -21.1% | -14.1% | -23.0% | -35.2% | |
| Operating ROA | -27.6% | -40.6% | -18.0% | -20.1% | -36.7% | |
| Return on tangible assets | -21.6% | -21.1% | -14.1% | -23.0% | -35.2% | |
| Return on equity | -22.3% | -21.9% | -14.4% | -23.8% | -37.9% | |
| Return on invested capital | -25.8% | -23.0% | -19.6% | -23.4% | -37.5% | |
| Return on capital employed | -25.8% | -23.0% | -19.6% | -23.5% | -37.6% | |
| Earnings yield | -7.6% | -25.7% | -1.8% | -2.4% | -5.4% | |
| Free cash flow yield | -6.4% | -17.8% | 0.0% | -2.7% | -5.2% | |
| Capex / Op. cash flow | -0.2% | -0.3% | 0.0% | -0.0% | -0.2% | |
| Capex / Depreciation | 251.8% | 700.0% | 0.0% | 1.8% | 47.3% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 18272d | 46801d | 0d | 1069d | 4480d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -18272d | -46801d | 0d | -1069d | -4480d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+324.7%EV / Sales n/aEV / EBITDA ▼-294.1%EV / Op. cash flow ▼-10.583Earnings yield ▲+0.181
Profitability
Return on equity ▼-0.004Return on assets ▼-0.004Return on invested capital ▼-0.028Return on capital employed ▼-0.028Operating ROA ▲+0.130Income quality ▲+0.146Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-28529.123Operating cycle n/aCash conversion cycle ▲+28529.123Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-6.528Net debt / EBITDA ▼-0.310Working capital ▼-35343000.000Invested capital ▼-34263000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+285.4%EV / Sales n/aEV / EBITDA ▲+20.2%EV / Op. cash flow ▲+1.138Earnings yield ▼-0.022
Profitability
Return on equity ▲+0.155Return on assets ▲+0.136Return on invested capital ▲+0.118Return on capital employed ▲+0.118Operating ROA ▲+0.091Income quality ▼-0.134Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+13791.713Operating cycle n/aCash conversion cycle ▼-13791.713Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+6.808Net debt / EBITDA ▼-2.322Working capital ▲+277560000.000Invested capital ▲+279193000.000Intangibles / Total assets n/a